We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+16.29%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$7.82B
AUM Growth
+$1.31B
Cap. Flow
+$158M
Cap. Flow %
2.03%
Top 10 Hldgs %
19.27%
Holding
869
New
65
Increased
350
Reduced
240
Closed
81

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$43.7M
2
BMY icon
Bristol-Myers Squibb
BMY
+$30.4M
3
GILD icon
Gilead Sciences
GILD
+$28.3M
4
BIIB icon
Biogen
BIIB
+$26.7M
5
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$25.2M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$75.2M
2
LOXO
Loxo Oncology, Inc
LOXO
+$28.1M
3
DHR icon
Danaher
DHR
+$27.9M
4
A icon
Agilent Technologies
A
+$26.4M
5
MKC icon
McCormick & Company Non-Voting
MKC
+$18M

Sector Composition

Rank Sector Weight
1 Healthcare 33.36%
2 Technology 15.96%
3 Financials 11.25%
4 Consumer Discretionary 8.98%
5 Communication Services 7.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSLA icon
151
Tesla
TSLA
$1.24T
$12.5M 0.16%
671,625
+26,940
+4% +$541K
GIS icon
152
General Mills
GIS
$19.2B
$12.5M 0.16%
241,215
+67,709
+39% +$3.07M
ED icon
153
Consolidated Edison
ED
$41.6B
$12.4M 0.16%
145,846
+13,122
+10% +$1.05M
NKE icon
154
Nike
NKE
$61.9B
$12.2M 0.16%
144,831
-248
-0.2% -$20.5K
KMB icon
155
Kimberly-Clark
KMB
$36.4B
$12.1M 0.15%
97,252
+59,985
+161% +$6.97M
MGNX icon
156
MacroGenics
MGNX
$235M
$12M 0.15%
665,488
+122,501
+23% +$2.12M
COF icon
157
Capital One
COF
$124B
$12M 0.15%
146,466
+2,978
+2% +$242K
CMA
158
DELISTED
Comerica
CMA
$11.8M 0.15%
161,433
+78,920
+96% +$6.33M
BOLD
159
DELISTED
Audentes Therapeutics, Inc
BOLD
$11.7M 0.15%
300,800
– –
PDD icon
160
Pinduoduo
PDD
$118B
$11.6M 0.15%
+469,600
New +$12.6M
DE icon
161
Deere & Co
DE
$170B
$11.5M 0.15%
72,227
-10,533
-13% -$1.68M
HCA icon
162
HCA Healthcare
HCA
$84.8B
$11.5M 0.15%
87,933
-85,013
-49% -$11.4M
TD icon
163
Toronto Dominion Bank
TD
$198B
$11.4M 0.15%
210,843
+11,874
+6% +$656K
MKC icon
164
McCormick & Company Non-Voting
MKC
$13.4B
$11.4M 0.15%
151,890
-266,542
-64% -$18M
AMP icon
165
Ameriprise Financial
AMP
$46.8B
$11.3M 0.15%
78,464
-3,012
-4% -$374K
EXC icon
166
Exelon
EXC
$48.6B
$11.2M 0.14%
314,237
+162,493
+107% +$5.53M
XLRN
167
DELISTED
Acceleron Pharma
XLRN
$11.2M 0.14%
240,500
-2,258
-0.9% -$99.1K
XRAY icon
168
Dentsply Sirona
XRAY
$2.59B
$11.2M 0.14%
225,732
+86,970
+63% +$3.83M
CCL icon
169
Carnival Corporation Ltd
CCL
$36.1B
$11.2M 0.14%
220,426
-14,251
-6% -$790K
SPPI
170
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$11.2M 0.14%
1,044,900
+65,075
+7% +$697K
CAT icon
171
Caterpillar
CAT
$409B
$11M 0.14%
81,247
+3,531
+5% +$469K
BA icon
172
Boeing
BA
$165B
$10.9M 0.14%
28,673
-141
-0.5% -$54.3K
KPTI icon
173
Karyopharm Therapeutics
KPTI
$168M
$10.9M 0.14%
124,452
+4,949
+4% +$549K
ARWR icon
174
Arrowhead Research
ARWR
$12.1B
$10.9M 0.14%
594,000
– –
DHI icon
175
D.R. Horton
DHI
$41B
$10.9M 0.14%
262,379
-16,883
-6% -$661K
5 6
7
8 9

Similar funds

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
A
AustralianSuper Melbourne, Australia $19.2B AUM 31.95% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $19.1B AUM 26.9% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return

Candriam SCA's Q1 2019 Portfolio in Review

As of Q1 2019, Candriam SCA held 869 positions worth $7.82B, up 20% from $6.51B the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Candriam SCA's Q1 2019 filing shows 65 new, 350 increased, 240 reduced and 81 closed positions. Its largest new stake was Baozun: 640,000 shares worth $26.6M. The largest sale was Celgene Corp, an estimated $75.2M.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 35% a quarter earlier, followed by Technology and Financials.

  • Candriam SCA's largest Q1 2019 buy was Baozun: 640,000 shares worth $26.6M.
  • Candriam SCA added most to Merck in Q1 2019, an estimated $43.7M increase.
  • Candriam SCA's biggest Q1 2019 reduction was Celgene Corp, cutting an estimated $75.2M.
  • Candriam SCA fully exited Loxo Oncology, Inc in Q1 2019, selling an estimated $28.1M.
  • Candriam SCA's ten largest holdings make up 19% of its $7.82B portfolio in Q1 2019.
  • Candriam SCA opened 65 new positions and closed 81 in Q1 2019.
  • Candriam SCA's portfolio value rose 20% quarter-over-quarter to $7.82B.

Based on Candriam SCA's 13F filing for Q1 2019, filed 2 May 2019.